Business Wire

AGERAS

6.12.2022 08:01:44 CET | Business Wire | Press release

Share
Ageras Launches Small-Biz Inflation Tracker, Finds Inflation Rates Outpacing Prices Charged by Europe’s Smallest Businesses

Ageras, the leading fintech company utilizing its banking and accounting software to power more than one million small businesses across Europe and the United States, announced today that it launched its proprietary Inflation Tracker, revealing how the rise in the Consumer Price Index dramatically outpaced the rise in prices billed by Europe’s small businesses across seven Western European economies in the most recent quarter.

By comparing how much tens of thousands of freelancers, microbusinesses, and other SMEs raised the prices for the same set of goods via Ageras’ accounting software between July through September versus the rise in each country’s official Consumer Price Index, Ageras data provides insight into how the smallest business owners across some of Europe’s largest economies are faring relative to overall inflation rates.

“We launched our index because we wanted to objectively study and highlight the unique challenges facing the economy's unsung heroes — sole proprietors and other small businesses,” said Ageras Co-founder Martin Hegelund. “Our data in this inaugural report show that inflation left small business owners worse off in every country we studied. We hope these data are a wake-up call for policymakers to focus more on inflation’s outsized impact on small businesses.”

Ageras’ index focused on seven European economies--Austria, Belgium, Denmark, France, Germany, Switzerland, and the United Kingdom. It chose these countries because Ageras’ software suite is most heavily used there, and its dataset is strongest. Ageras’ future index reports will expand the countries it studies.

In Europe’s largest economies, the CPI rose between 2% to 3% faster than price hikes by small businesses. In France and Germany, there was a 2.6% gap between official CPI data and SMEs studied by Ageras. In the United Kingdom, inflation’s impact was slightly weaker. Prices there rose 2.2% faster than SMEs raised their prices.

However, inflation’s largest impact was across some of Western Europe’s small countries in the most recent quarter.

Among the seven countries that Ageras’ index measured, inflation’s impact hit SMEs in Austria hardest. Austria’s CPI rose 5.3% faster than small businesses raised their prices last quarter. The gap was second highest in Belgium at 4.4%, followed by Denmark at 4.2%. Small business owners were best off in Switzerland, where the CPI rose 0.8% faster than SMEs raised the price of their goods.

Here are the full country reports (alphabetically ordered) using Ageras’ proprietary dataset:

Austria:
Ageras data show small business owners in Austria raised their prices by 4.5% in Q3 of 2022 compared to the third quarter of 2021. That lagged behind the 9.8% rise in Austria’s CPI during the same time period.

Belgium:
Ageras data show small business owners in Belgium raised their prices by 5.9% in the third quarter compared to the last year. That was dwarfed by the 10.3% rise in Belgium’s CPI during the same period.

Denmark:
Ageras data show small business owners in Denmark raised their prices by 5% in Q3. That rate trailed the 9.2% rise in Denmark’s latest CPI.

France:
Ageras data show small business owners in France raised their prices by 3.2% in Q3. That was lower than the 5.8% rise in France’s Q3 CPI.

Germany:
Ageras data show small business owners in Germany raised their prices by 5.9% in Q3 2022 compared to last year. That rate was below the 8.5% rise in Germany’s Q3 CPI.

Switzerland:
Ageras data show small business owners in Switzerland raised their prices by 2.6% in Q3. During that same time period, Switzerland’s CPI rose at a higher rate, 3.4%.

United Kingdom:
Ageras data show small business owners in the United Kingdom raised their prices by 6.5% in Q3 2022. That rate was less than the 8.7% rise in the UK’s CPI last quarter.

About Ageras:

Ageras is the ultimate fintech platform for small business owners. Its one-stop platform integrates its solutions into a single “financial cockpit” for invoicing, accounting, payroll, and banking, enabling small business owners and entrepreneurs to focus on what they do best: running their businesses. Ageras began as the online marketplace Ageras.com (matching SMEs with accountants) and has expanded into a 350-person company offering a complete ecosystem of tools and services for SMEs. Today, Ageras offers cloud-based accounting software through its products Zervant, Billy, and Tellow, banking through Kontist, and payroll software through Salary. In late 2021, the group launched an embedded fintech service that directly provides financing options to its customers through its software. Ageras’ solutions have been used by more than one million small businesses across Europe and the U.S. The company was founded in 2012 by serial entrepreneurs Rico Andersen and Martin Hegelund, who have 25 years of combined experience building internet companies. For more information, please visit www.ageras.group.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005038/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye